Download PDF
Dtsch Med Wochenschr 2015; 140(14): 1056-1062
DOI: 10.1055/s-0041-102928
Dossier
Chronische Lebererkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Heilung der chronischen Virushepatitis B und C: Vision versus Realität

Cure of chronic Hepatitis B and C: vision versus reality
Tobias Boettler
1   Klinik für Innere Medizin II, Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie, Universitätsklinikum Freiburg
,
Robert Thimme
1   Klinik für Innere Medizin II, Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie, Universitätsklinikum Freiburg
,
Christoph Neumann-Haefelin
1   Klinik für Innere Medizin II, Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie, Universitätsklinikum Freiburg
› Author Affiliations
Further Information

Publication History

Publication Date:
16 July 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Etwa 500 Millionen Menschen sind chronisch mit dem Hepatitis B oder C Virus (HBV bzw. HCV) infiziert. Die chronische Hepatitis B bzw. C kann über eine chronische Leberentzündung und eine Leberzirrhose bis zum hepatozellulären Karzinom (HCC) führen. Grundlagenwissenschatlichen Erkenntnissen zum Lebenszyklus von HCV ermöglichten die Entwicklung direkt-antiviraler Therapien, die heute bei der großen Mehrheit der Patienten eine Virusausheilung ermöglicht. Eine wichtige Herausforderung für die Zukunft ist die Entwicklung einer HCV-spezifischen Impfung. Der Lebenszyklus von HBV beinhaltet eine Integration der viralen cccDNA in den Zellkern der Hepatozyten. Aufgrund dieses Persistenzreservoirs ist eine Virusausheilung bei der chronischen Hepatitis B selten zu erreichen; Therapieziel bei der Therapie mit pegyliertem Interferon-alfa oder Nukleosid-/ Nukleotidanaloga ist die dauerhafte Virussuppression. Die kürzliche Entdeckung des HBV-Zellrezeptors sowie immunmodulatorische Strategien könnten zur Optimierung der HBV-Therapie bis hin zur Viruselimination beitragen.

Abstract

Approximately 500 million individuals are chronically infected with hepatitis B or C virus (HBV or HCV). Chronic hepatitis B or C can cause liver inflammation, cirrhosis, and ultimately hepatocellular carcinoma (HCC). Advances in basic science regarding the HCV life cycle contributed to the development of direct-acting antivirals, allowing viral elimination in the large majority of currently treated patients. A major challenge for future research is the development of an HCV-specific vaccination. The HBV life cycle involves the integration of viral cccDNA into the nucleolus of the hepatocytes. Due to this reservoir of persistence, viral elimination is rarely achieved during chronic HBV infection. Aim of antiviral therapy based on pegylated interferon-alfa or nucleoside / nucleotide analogues is a sustained viral control. The recent identification of the HBV cell receptor as well immunomodulatory strategies may help to optimize HBV therapy and eventually allow viral elimination.

Schlüsselwörter

Hepatitis B - Hepatitis C - molekulare Virologie - Pathogenese - antivirale Therapie

Keywords

Hepatitis B - hepatitis C - molecular virology - pathogenesis - antiviral therapy
 

  • Literatur

  • 1 Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687
    CrossrefPubMedGoogle Scholar
  • 2 Barnes E, Folgori A, Capone S et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4: 115ra111
    PubMedGoogle Scholar
  • 3 Bengsch B, Seigel B, Ruhl M et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS pathogens 2010; 6: e1000947
    CrossrefPubMedGoogle Scholar
  • 4 Boni C, Laccabue D, Lampertico P et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963-973, e969
    CrossrefPubMedGoogle Scholar
  • 5 Buchmann P, Dembek C, Kuklick L et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31: 1197-1203
    CrossrefPubMedGoogle Scholar
  • 6 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185
    CrossrefPubMedGoogle Scholar
  • 7 Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12: 190-197
    PubMedGoogle Scholar
  • 8 Glebe D, Bremer CM. The Molecular Virology of Hepatitis B Virus. Semin Liver Dis 2013; 33: 103-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Godon O, Fontaine H, Kahi S et al. Immunological and Antiviral Responses After Therapeutic DNA Immunization in Chronic Hepatitis B Patients Efficiently Treated by Analogues. Mol Ther 2014; 22: 675-684
    CrossrefPubMedGoogle Scholar
  • 10 Kitrinos KM, Corsa A, Liu Y et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59: 434-442
    CrossrefPubMedGoogle Scholar
  • 11 Kittner JM, Sprinzl MF, Grambihler A et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012; 54: 93-95
    CrossrefPubMedGoogle Scholar
  • 12 Koniger C, Wingert I, Marsmann M et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA 2014; 111: E4244-4253
    PubMedGoogle Scholar
  • 13 Kosinska AD, Zhang E, Johrden L et al. Combination of DNA Prime – Adenovirus Boost Immunization with Entecavir Elicits Sustained Control of Chronic Hepatitis B in the Woodchuck Model. PLoS pathogens 2013; 9: e1003391
    PubMedGoogle Scholar
  • 14 Liang TJ, Ghany MG. Therapy of hepatitis C – back to the future. N Engl J Med 2014; 370: 2043-2047
    CrossrefPubMedGoogle Scholar
  • 15 Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol 2013; 369: 167-198
    PubMedGoogle Scholar
  • 16 Lohmann V, Korner F, Koch J et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-13
    CrossrefPubMedGoogle Scholar
  • 17 Lucifora J, Xia Y, Reisinger F et al. Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science 2014; 343: 1221-1228
    CrossrefPubMedGoogle Scholar
  • 18 Lupberger J, Zeisel MB, Xiao F et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595
    CrossrefPubMedGoogle Scholar
  • 19 Martin B, Hennecke N, Lohmann V et al. Restoration of HCV-specific CD8+ T-cell function by Interferon-free therapy. J Hepatol 2014; 61
    PubMedGoogle Scholar
  • 20 Martin P, Dubois C, Jacquier E et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 2015; DOI: 10.1136/gutjnl-2014–308041.
    PubMedGoogle Scholar
  • 21 Micco L, Peppa D, Loggi E et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013; 58: 225-233
    CrossrefPubMedGoogle Scholar
  • 22 Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 2013; 369: 113-142
    PubMedGoogle Scholar
  • 23 Ni Y, Lempp FA, Mehrle S et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146: 1070-1083, e1076
    CrossrefPubMedGoogle Scholar
  • 24 Nkongolo S, Ni Y, Lempp FA et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014; 60: 723-731
    CrossrefPubMedGoogle Scholar
  • 25 Sarrazin C, Berg T, Buggisch P et al. Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. Z Gastroenterol 2015; 53: 320-334
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Serti E, Chepa-Lotrea X, Kim YJ et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology 2015; DOI: 10.1053/j.gastro.2015.03.004.
    PubMedGoogle Scholar
  • 27 Stegmann KA, Bjorkstrom NK, Veber H et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010; 138: 1885-1897
    CrossrefPubMedGoogle Scholar
  • 28 Swadling L, Capone S, Antrobus RD et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014; 6: 261ra153
    CrossrefPubMedGoogle Scholar
  • 29 Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21: 33-40
    CrossrefPubMedGoogle Scholar
  • 30 Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis B?. J Hepatol 2013; 58: 205-209
    PubMedGoogle Scholar
  • 31 Thimme R, Heim M, Baumert TF et al. Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie. Teil 1: Hepatitis-B-Virus. Dtsch Med Wochenschr 2014; 139: 655-659
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Thimme R, Heim M, Baumert TF et al. Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie. Teil 2: Hepatitis-C-Virus. Dtsch Med Wochenschr 2014; 139: 778-782
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Thimme R, Wieland S, Steiger C et al. CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection. J Virol 2003; 77: 68-76
    CrossrefPubMedGoogle Scholar
  • 34 Volz T, Allweiss L, Barek MB et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861-867
    CrossrefPubMedGoogle Scholar
  • 35 Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796
    CrossrefPubMedGoogle Scholar
  • 36 Wherry EJ, Ha SJ, Kaech SM et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27: 670-684
    CrossrefPubMedGoogle Scholar
  • 37 Yan H, Zhong G, Xu G et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049
    PubMedGoogle Scholar
  • 38 Yoshimi S, Imamura M, Murakami E et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol 2015; DOI: 10.1002/jmv.24255:n/a-n/a.
    PubMedGoogle Scholar
  • 39 Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr Top Microbiol Immunol 2013; 369: 87-112
    PubMedGoogle Scholar